[Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].
Selimova
L M
LM
Kraevskiĭ
A A
AA
Galegov
G A
GA
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001386:Azides / Q000008:administration & dosage / Q000494:pharmacology*; D002460:Cell Line; D004352:Drug Resistance, Microbial; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D013936:Thymidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology*
C405002:3'-azido-3'-deoxythymidine-5'-H-phosphonate; D019380:Anti-HIV Agents; D001386:Azides; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019469:Indinavir; D013936:Thymidine